Here, using MSCs from Ahr-deficient mice, we demonstrated decreased iNOS protein expression and NO production which reduced the inhibition of T-cell proliferation and decreased the therapeutic efficacy in GVHD compared to wild-type (WT)-MSCs. Here, AHR is linked to graft versus host disease.